+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Savolitinib Tablets Market - Global Forecast 2026-2032- Product Image
Savolitinib Tablets Market - Global Forecast 2026-2032- Product Image
Sale

Savolitinib Tablets Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6129294
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Savolitinib Tablets Market is projected to reach USD 2.09 Billion in 2026. It is expected to continue growing at a CAGR of 10.38%, reaching USD 3.78 Billion by 2032.

Savolitinib Tablets: Executive Summary and Market Context

Savolitinib tablets are an oral, targeted oncology therapy associated with inhibition of the MET pathway. Their clinical relevance is linked to cancers in which MET dysregulation contributes to tumor growth or treatment resistance, particularly biomarker-defined non-small-cell lung cancer settings. Adoption depends on regulatory authorization, companion-diagnostic availability, evidence quality, prescribing guidance, reimbursement, and patient access. This summary focuses on evidence-based structural, regional, group, country, technology, and implementation considerations without presenting market estimates or forecasts.

Biomarker-Led Oncology Is Reshaping Savolitinib Adoption

The landscape is shifting from broad treatment categories toward biomarker-led care. For savolitinib, this places testing quality, specimen adequacy, laboratory turnaround, and alignment between diagnostic results and treatment eligibility at the center of clinical implementation. Evidence generation is also moving toward more precisely defined patient populations, real-world effectiveness, treatment sequencing, and management of adverse events. Access decisions increasingly depend on the strength and maturity of clinical evidence, as well as the ability of health systems to identify appropriate patients consistently.

Artificial Intelligence Strengthens Diagnosis, Evidence Generation, and Safety Management

Artificial intelligence can support the savolitinib treatment pathway by improving radiology and pathology workflows, identifying potentially relevant MET alterations, and prioritizing cases for confirmatory testing. It may also assist clinical-trial recruitment, record-based patient identification, response assessment, and pharmacovigilance signal detection. These uses remain dependent on validated datasets, transparent performance evaluation, privacy safeguards, and clinician oversight. AI should complement-not replace-molecular confirmation, multidisciplinary review, and regulatory standards for treatment decisions.

Regional Differences Reflect Diagnostic Capacity, Regulation, and Access Pathways

North America generally combines advanced oncology infrastructure with established molecular-testing networks, although reimbursement and coverage policies can differ by payer and jurisdiction. Europe’s implementation is shaped by national health technology assessment, European regulatory processes, and variation among health systems. Asia-Pacific includes strong pharmaceutical and clinical-research capabilities alongside substantial differences in testing access and treatment affordability. Latin America faces uneven diagnostic infrastructure, procurement constraints, and access disparities. The Middle East is characterized by concentrated specialist capacity in selected healthcare hubs and variable national coverage. Africa requires particular attention to pathology capacity, referral networks, affordability, and continuity of oncology care. Across all regions, reliable MET testing and coordinated patient pathways are fundamental to appropriate use.

International Groups Highlight Shared Standards but Uneven Implementation

ASEAN countries show diverse regulatory systems, healthcare financing structures, and molecular-diagnostics capabilities, making regional coordination valuable. BRICS members span major oncology centers and substantial internal disparities in access, reimbursement, and laboratory capacity. The European Union benefits from shared regulatory and scientific frameworks, while implementation remains nationally organized. G7 health systems generally possess strong research and diagnostic capabilities but still face affordability, workforce, and evidence-translation challenges. GCC states often have centralized purchasing and specialist care networks that can support rapid protocol adoption where coverage is established. NATO members do not represent a unified healthcare market, yet their cooperation can support research resilience, supply-chain continuity, and health-security planning.

Country-Level Priorities Range from Evidence Generation to Diagnostic Expansion

Australia combines specialist oncology services with geographically dispersed populations, making tele-oncology and coordinated testing relevant. Brazil and Mexico must address regional differences in public and private access, laboratory capacity, and reimbursement. Canada’s decentralized health system places emphasis on provincial assessment and coordinated diagnostic pathways. China and India have expanding oncology capabilities but substantial variation between major centers and underserved areas. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have established oncology systems, with national or regional differences in approval, assessment, reimbursement, and testing implementation. Russia’s access environment is influenced by domestic regulation, procurement, and healthcare-system constraints. In the United States, coverage variation, molecular-testing pathways, and specialist prescribing practices are important determinants of use. Across these countries, reliable biomarker confirmation and monitoring capacity remain central.

Priorities for Leaders: Connect Testing, Treatment, Access, and Evidence

Industry leaders should build treatment pathways around validated MET testing, including clear specimen guidance, laboratory partnerships, rapid result reporting, and mechanisms for repeat testing when clinically appropriate. They should generate transparent evidence on patient selection, treatment sequencing, outcomes, tolerability, and management in routine practice, while engaging regulators, payers, clinicians, and patient groups early. Access strategies should account for public-sector procurement, diagnostic reimbursement, affordability, and regional referral patterns rather than focusing only on product availability. Responsible AI adoption should use validated tools, human review, bias monitoring, and strong data governance. Supply continuity, clinician education, and patient-support programs should be designed to reinforce appropriate use and long-term adherence.

Research Methodology: Evidence-Based Review of Clinical and Health-System Factors

This executive summary uses the supplied market subject as a scope definition and applies a structured qualitative review framework. The assessment organizes evidence around the therapy’s mechanism and clinical context, biomarker testing, regulatory and reimbursement considerations, healthcare delivery, regional and country-level implementation, artificial intelligence, and operational priorities. Claims are limited to established market-structure and healthcare-system observations; no market estimates, shares, forecasts, or company-specific comparisons are included. Interpretation should be updated as regulatory decisions, clinical evidence, diagnostic standards, and national access policies evolve.

Conclusion: Appropriate Use Depends on Biomarker Precision and System Readiness

Savolitinib tablets sit within a rapidly evolving, biomarker-driven oncology environment. Their practical impact depends not only on clinical evidence but also on dependable MET testing, coordinated specialist care, equitable reimbursement, patient monitoring, and resilient supply and referral systems. Regional and national conditions differ substantially, so successful implementation requires locally adapted pathways supported by consistent quality standards. Leaders that connect diagnostics, evidence generation, responsible technology use, and access planning will be better positioned to support appropriate patient selection and durable clinical value.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Savolitinib Tablets Market, by Indication
7.1. Introduction
7.2. Gastric Cancer
7.3. Non-Small Cell Lung Cancer
7.3.1. C-Met Exon 14 Skipping Mutation Positive
7.3.2. Egfr Mutation Positive
7.4. Renal Cell Carcinoma
8. Savolitinib Tablets Market, by Dosage Strength
8.1. Introduction
8.2. 100 Mg
8.3. 200 Mg
9. Savolitinib Tablets Market, by Line Of Therapy
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line And Beyond
10. Savolitinib Tablets Market, by Patient Type
10.1. Introduction
10.2. Adult
10.3. Pediatric
11. Savolitinib Tablets Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Savolitinib Tablets Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Savolitinib Tablets Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Savolitinib Tablets Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Amgen Inc.
16.3. Astellas Pharma Inc.
16.4. AstraZeneca PLC
16.5. Bayer AG
16.6. BeiGene, Ltd.
16.7. Boehringer Ingelheim International GmbH
16.8. Bristol-Myers Squibb Company
16.9. Daiichi Sankyo Company, Limited
16.10. Eli Lilly and Company
16.11. Gilead Sciences, Inc.
16.12. GlaxoSmithKline plc
16.13. HUTCHMED (China) Limited
16.14. Immunomedics, Inc.
16.15. Ipsen S.A.
16.16. Merck & Co., Inc.
16.17. Novartis AG
16.18. Pfizer Inc.
16.19. Roche Holding AG
16.20. Sanofi S.A.
16.21. Seattle Genetics, Inc.
16.22. Shanghai Hutchison Pharmaceuticals Company Limited
16.23. Takeda Pharmaceutical Company Limited
16.24. TissueTech, Inc.
16.25. WuXi STA Company
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Savolitinib Tablets Market, Years Considered for the Study
FIGURE 2. Global Savolitinib Tablets Market, Research Design
FIGURE 3. Global Savolitinib Tablets Market, Research Framework
FIGURE 4. Global Savolitinib Tablets Market, Data Triangulation
FIGURE 5. Global Savolitinib Tablets Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Savolitinib Tablets Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Savolitinib Tablets Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Savolitinib Tablets Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 9. Global Savolitinib Tablets Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Savolitinib Tablets Market Size, by Line Of Therapy, 2025 vs 2032 (%)
FIGURE 11. Global Savolitinib Tablets Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Savolitinib Tablets Market Size, by Patient Type, 2025 vs 2032 (%)
FIGURE 13. Global Savolitinib Tablets Market Size, by Patient Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Savolitinib Tablets Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Savolitinib Tablets Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Savolitinib Tablets Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Savolitinib Tablets Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Savolitinib Tablets Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Savolitinib Tablets Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Savolitinib Tablets Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Savolitinib Tablets Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Savolitinib Tablets Market Segmentation & Coverage
TABLE 2. Global Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 3. Global Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Gastric Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Gastric Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Gastric Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Non-Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Non-Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Non-Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global C-Met Exon 14 Skipping Mutation Positive Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global C-Met Exon 14 Skipping Mutation Positive Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global C-Met Exon 14 Skipping Mutation Positive Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Egfr Mutation Positive Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Egfr Mutation Positive Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Egfr Mutation Positive Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Renal Cell Carcinoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Renal Cell Carcinoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Renal Cell Carcinoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 20. Global 100 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global 100 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global 100 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global 200 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global 200 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global 200 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 27. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 37. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 44. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Savolitinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Savolitinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 61. North America Savolitinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. North America Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 63. North America Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 64. North America Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 65. North America Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 66. North America Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 67. North America Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 68. Latin America Savolitinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Latin America Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 70. Latin America Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 71. Latin America Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 72. Latin America Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 73. Latin America Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 74. Latin America Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 75. Europe Savolitinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Europe Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 77. Europe Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 78. Europe Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 79. Europe Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 80. Europe Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 81. Europe Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 82. Middle East Savolitinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Middle East Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 84. Middle East Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 85. Middle East Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 86. Middle East Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 87. Middle East Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 88. Middle East Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 89. Africa Savolitinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Africa Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 91. Africa Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 92. Africa Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 93. Africa Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 94. Africa Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 95. Africa Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. Global Savolitinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. ASEAN Savolitinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. ASEAN Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 99. ASEAN Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 100. ASEAN Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 101. ASEAN Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 102. ASEAN Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 103. ASEAN Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. GCC Savolitinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. GCC Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 106. GCC Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 107. GCC Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 108. GCC Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 109. GCC Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 110. GCC Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. European Union Savolitinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. European Union Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 113. European Union Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 114. European Union Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 115. European Union Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 116. European Union Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 117. European Union Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 118. BRICS Savolitinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. BRICS Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 120. BRICS Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 121. BRICS Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 122. BRICS Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 123. BRICS Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 124. BRICS Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 125. G7 Savolitinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. G7 Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 127. G7 Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 128. G7 Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 129. G7 Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 130. G7 Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 131. G7 Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. NATO Savolitinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. NATO Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. NATO Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 135. NATO Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 136. NATO Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 137. NATO Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 138. NATO Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. Global Savolitinib Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. United States Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 141. United States Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 142. United States Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 143. United States Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 144. United States Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 145. United States Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 146. United States Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. Canada Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 148. Canada Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 149. Canada Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 150. Canada Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 151. Canada Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 152. Canada Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 153. Canada Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. Mexico Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 155. Mexico Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 156. Mexico Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 157. Mexico Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 158. Mexico Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 159. Mexico Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 160. Mexico Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. Brazil Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 162. Brazil Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 163. Brazil Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 164. Brazil Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 165. Brazil Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 166. Brazil Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 167. Brazil Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. United Kingdom Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 169. United Kingdom Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. United Kingdom Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 171. United Kingdom Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 172. United Kingdom Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 173. United Kingdom Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 174. United Kingdom Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. Germany Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 176. Germany Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. Germany Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 178. Germany Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 179. Germany Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 180. Germany Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 181. Germany Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 182. France Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 183. France Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 184. France Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 185. France Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 186. France Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 187. France Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 188. France Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 189. Russia Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 190. Russia Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 191. Russia Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 192. Russia Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 193. Russia Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 194. Russia Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 195. Russia Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Italy Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 197. Italy Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 198. Italy Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 199. Italy Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 200. Italy Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 201. Italy Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 202. Italy Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. Spain Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 204. Spain Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 205. Spain Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 206. Spain Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 207. Spain Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 208. Spain Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 209. Spain Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. China Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 211. China Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 212. China Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 213. China Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 214. China Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 215. China Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 216. China Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 217. India Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 218. India Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 219. India Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 220. India Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 221. India Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 222. India Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 223. India Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 224. Japan Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 225. Japan Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 226. Japan Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 227. Japan Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 228. Japan Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 229. Japan Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 230. Japan Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 231. Australia Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 232. Australia Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 233. Australia Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 234. Australia Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 235. Australia Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 236. Australia Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 237. Australia Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 238. South Korea Savolitinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 239. South Korea Savolitinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. South Korea Savolitinib Tablets Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 241. South Korea Savolitinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 242. South Korea Savolitinib Tablets Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 243. South Korea Savolitinib Tablets Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 244. South Korea Savolitinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 245. Global Savolitinib Tablets Market Share, by Key Player, 2025
TABLE 246. Global Savolitinib Tablets Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol‑Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • HUTCHMED (China) Limited
  • Immunomedics, Inc.
  • Ipsen S.A.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Seattle Genetics, Inc.
  • Shanghai Hutchison Pharmaceuticals Company Limited
  • Takeda Pharmaceutical Company Limited
  • TissueTech, Inc.
  • WuXi STA Company

Related Topics

Related Reports

Osimertinib Mesylate Tablets Market - Global Forecast 2026-2032 - Product Image

Osimertinib Mesylate Tablets Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Vandetanib Tablets Market - Global Forecast 2026-2032 - Product Image

Vandetanib Tablets Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Sotorasib Tablets Market Report 2026 - Product Image

Sotorasib Tablets Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Fast Melt Tablets Market Report 2026 - Product Image

Fast Melt Tablets Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Enterprise Tablets - Global Strategic Business Report - Product Image

Enterprise Tablets - Global Strategic Business Report

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.